The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the Laboratory Corporation of America (LabCorp) COVID-19 RT-PCR Test that allows for testing of samples self-collected by patients at home using the Pixel by LabCorp COVID-19 Test home collection kit.

The LabCorp COVID-19 Test home collection kit includes a specific Q-tip-style cotton swab and saline for patients to collect a nasal sample. Once collected, the sample can be mailed to a LabCorp lab for testing. The nasal samples will be analyzed using LabCorp’s COVID-19 RT-PCR Test for the detection of nucleic acid from SARS-CoV-2, the virus that causes COVID-19. The kit is only available if recommended by a healthcare provider based on results of a COVID-19 questionnaire. 

Related Articles

The Company will initially make the self-collection kits available to healthcare workers and first responders in the coming weeks. Future updates on the availability of the self-collection kit can be found here

In a press statement, the FDA noted that the EUA only applies to LabCorp’s self-collection kit and is not a general authorization for other kits being developed for at-home collection of patient samples using other swabs, media, or tests. 

Continue Reading

“Specifically, for tests that include home sample collection, we worked with LabCorp to ensure the data demonstrated from at-home patient sample collection is as safe and accurate as sample collection at a doctor’s office, hospital or other testing site,” said FDA Commissioner Stephen M. Hahn, MD. “With this action, there is now a convenient and reliable option for patient sample collection from the comfort and safety of their home.”

For more information visit